Evidence map›Paper›PMID 42562965›Full record

ArticleNature medicine2026

Intracranial delivery of B7-H3-targeting CAR-T cells for recurrent glioblastoma: a phase 1 trial.

Yang Zhang, Xiaohan Chi, Rui Feng, Na Xian, Na Huang, Shengjun Sun, Xiaobin Zhao, Peng Zhang, Kang Liu, Yiwen Ma and 13 more

Abstract readClinical Trial, Phase I
PubMed Publisher
In one paragraph

Article in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Yang Zhang *Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Xiaohan Chi *Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Rui Feng *Tcelltech Biological Science and Technology, Fuzhou, China.ORCID http://orcid.org/0009-0002-3917-7471
Na XianTcelltech Biological Science and Technology, Fuzhou, China.
Na HuangDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Shengjun SunDepartment of Radiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Xiaobin ZhaoDepartment of Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Peng ZhangDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Kang LiuDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Yiwen MaDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Yu ZhangDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Kangna ZhangDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Sihui WangDepartment of Radiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Xianzhen ChenTcelltech Biological Science and Technology, Fuzhou, China.
Jindong ZhangTcelltech Biological Science and Technology, Fuzhou, China.
Wuqing HuangDepartment of Epidemiology and Health Statistics, School of Public Health, Fujian Medical University, Fuzhou, China.
Baozhu HuangDepartment of Immunobiology and Medicine (Medical Oncology), Yale University School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0009-0006-3368-2062
Tina Tianjiao SuDepartment of Immunobiology and Medicine (Medical Oncology), Yale University School of Medicine, New Haven, CT, USA.
Jacky YeungDepartment of Immunobiology and Medicine (Medical Oncology), Yale University School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0001-7336-5738
Jianwei HeDepartment of Immunobiology and Medicine (Medical Oncology), Yale University School of Medicine, New Haven, CT, USA.
Lieping ChenDepartment of Immunobiology and Medicine (Medical Oncology), Yale University School of Medicine, New Haven, CT, USA. lieping.chen@yale.edu.ORCID http://orcid.org/0000-0002-6825-3069
Nan JiDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. jinan@mail.ccmu.edu.cn.ORCID http://orcid.org/0000-0002-9001-8858
Gangxiong HuangTcelltech Biological Science and Technology, Fuzhou, China. ghuang@tcelltech.com.ORCID http://orcid.org/0000-0002-0117-5457

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recurrent glioblastoma (rGBM) is a leading brain malignancy with few therapeutic options. Here we present the complete results of a phase 1 trial investigating the safety and efficacy of autologous B7-H3-targeting chimeric antigen receptor T (CAR-T) cell (TX103) therapy for the treatment of rGBM. In this open-label, 3 + 3 dose-escalation trial, patients aged 18-75 years with B7-H3-positive (≥30%) rGBM received intracranial infusion of TX103 at three dose levels (DLs-2 × 10

Indexed as

B7 AntigensBrain NeoplasmsGlioblastomaImmunotherapy, AdoptiveNeoplasm Recurrence, LocalReceptors, Chimeric AntigenAdolescentAdultAgedFemaleHumansMaleMaximum Tolerated DoseMiddle AgedTreatment OutcomeYoung AdultB7 AntigensCD276 protein, humanReceptors, Chimeric Antigen

Identifiers

PMID42562965

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.